12 June 2025
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
13 June 2023
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
12 June 2025
Ipsen announces issuance of €500 million inaugural Rated Public Bond
12 June 2025
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in…
12 June 2025
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 139 Press Releases
12 June 2025
12 June 2025
LinkedIn
Facebook
Ipsen announces issuance of €500 million inaugural Rated Public Bond
Transaction follows Investment Grade ratings assignment from both S&P and Moody’s
12 June 2025
12 June 2025
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.Confirmation of full-year 2025 financial guidance. PARIS,…
12 June 2025
12 June 2025
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
PARIS, FRANCE, 24 April 2025 Ipsen (Euronext: IPN; ADR: IPSEY) will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver (EASL) congress as…
12 June 2025
12 June 2025
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will serve on the Executive Leadership…
12 June 2025
12 June 2025
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
PARIS, France, 31 May 2025 – Late-breaking (LBA4175) post-hoc analysis data from the Phase III NAPOLI 3 study were presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These results found a median overall survival (mOS)…
Your dedicated contacts
-
Media Relations
